Blog
RSS FeedPosted by Michael Wonder on 26 Jun 2024
Health Canada authorizes Lilly's Ebglyss (lebrikizumab) for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older
25 June 2024 - Patients treated with Ebglyss experienced significant skin clearance and itch relief as early as 4 weeks. ...
Posted by Michael Wonder on 25 Jun 2024
Valneva announces Health Canada approval of the world’s first chikungunya vaccine, Ixchiq
24 June 2024 - Valneva today announced that Health Canada has approved Ixchiq, Valneva’s single-dose vaccine for the prevention of ...
Posted by Michael Wonder on 22 Jun 2024
Takeda's HyQvia approved as replacement therapy for primary humoral immunodeficiency and secondary humoral immunodeficiency in paediatric patients 2 years of age and older
21 June 2024 - Takeda Canada is pleased to announce that Health Canada has expanded the marketing authorisation for HyQvia (normal ...
Posted by Michael Wonder on 18 Jun 2024
Awiqli - world's first once-weekly basal insulin - now available in Canada
17 June 2024 - Novo Nordisk is pleased to announce Canada will be the first country worldwide to launch Awiqli (insulin ...
Posted by Michael Wonder on 13 Jun 2024
Adtralza (tralokinumab) pre-filled pen now available in Canada
12 June 2024 - The single-use 2 mL pre-filled pen is an additional injection choice for administering Adtralza for the ...
Posted by Michael Wonder on 01 Jun 2024
New analysis examines role of conditional approvals on access to promising oncology therapies
31 May 2024 - Health Canada’s Notice of Compliance with conditions (NOC/c) policy has been effective in providing people in Canada ...
Posted by Michael Wonder on 30 May 2024
Improving our assessments of drugs with companion diagnostic tests
30 May 2024 - As part of our ongoing initiative to improve and modernise our reimbursement review program, Canada’s Drug Agency ...
Posted by Michael Wonder on 28 May 2024
The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study
27 May 2024 - The Patented Medicine Prices Review Board (PMPRB), the agency that regulates the prices of patented medicines in ...
Posted by Michael Wonder on 25 May 2024
Moving forward on Pharmacare for Canadians
24 May 2024 - Pharmacare legislation includes universal access to contraception and diabetes medications. ...
Posted by Michael Wonder on 24 May 2024
Bausch Health announces additional public drug plan listings for Uceris (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults
23 May 2024 - Bausch Health today announced additional Canadian public drug plan listings for Uceris (budesonide) aerosol foam to ...
Posted by Michael Wonder on 23 May 2024
PMPRB report examines availability and pricing of new medicines
22 May 2024 - The Patented Medicine Prices Review Board (PMPRB) published the eighth edition of its annual Meds Entry Watch ...
Posted by Michael Wonder on 23 May 2024
Pfizer announces availability of Abrysvo in Canada for immunisation of pregnant individuals and adults 60+
22 May 2024 - Availability of Arbysvo is a major step in protecting infants and adults 60 years of age ...
Posted by Michael Wonder on 23 May 2024
Health Canada approves Cosentyx, a biologic therapy, for the treatment of adults with moderate to severe hidradenitis suppurativa
22 May 2024 - Approval is based on the two largest Phase 3 trials conducted in hidradenitis suppurativa – SUNSHINE and SUNRISE ...
Posted by Michael Wonder on 22 May 2024
The National Advisory Committee on Immunization recommends Beyfortus to protect all infants against RSV
21 May 2024 - The National Advisory Committee on Immunization issued a recommendation for Beyfortus (nirsevimab) to be used for the ...
Posted by Michael Wonder on 17 May 2024
Health Canada approves Saladax’s 5-fluorouracil chemotherapy therapeutic drug monitoring test
14 May 2024 - Saladax Biomedical is pleased to announce that Health Canada has approved Saladax’s 5-Fluorouracil (My5-FU) Assay for sale ...